SCHEMBL2385054

SCHEMBL2385054

Cc1cc(C)cc(-c2cc3c4cc(C)ccc4n(C)c3n(C)c2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ PKM P14618 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ APAF1 O14727 1/20 0.46
▸ IDO1 P14902 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ MCL1 Q07820 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ BRD9 Q9H8M2 1/20 0.42
▸ BRD7 Q9NPI1 1/20 0.42
▸ PGR P06401 1/20 0.37
▸ RORA P35398 1/20 0.37
▸ RORC P51449 1/20 0.37
▸ RORB Q92753 1/20 0.37
▸ BCHE P06276 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385267 0.88 KDM4E (0.43) MAPTKDM4EPKMHTTAPAF1
SCHEMBL3867984 0.87 HSD17B10 (0.46) MAPTKDM4EPKMHTTAPAF1
SCHEMBL2382248 0.85 MAPT (0.43) MAPTKDM4EPKMHTTAPAF1
SCHEMBL3443882 0.85 KDM4E (0.43) MAPTKDM4EPKMHTTAPAF1
Hydrochloric Acid SCHEMBL3444526 0.84 KDM4E (0.42) MAPTKDM4EPKMHTTAPAF1
SCHEMBL3445477 0.83 KDM4E (0.40) MAPTKDM4EPKMHTTAPAF1
SCHEMBL2384727 0.83 KDM4E (0.49) MAPTKDM4EPKMHTTAPAF1
SCHEMBL5739997 0.83 KDM4E (0.41) MAPTKDM4EPKMHTTAPAF1
SCHEMBL3867457 0.83 KDM4E (0.41) MAPTKDM4EPKMHTTAPAF1
SCHEMBL2384414 0.83 PADI4 (0.44) MAPTKDM4EPKMHTTAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012991-B2 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate SANOFI-AVENTIS (FR) 2011-09-06 — — US disclosed
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2008-09-04 — — US disclosed
US-7390818-B2 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-06-24 — — US disclosed
EP-1556382-B1 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-05-28 — — EP disclosed
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2005-12-29 — — US disclosed
EP-1556382-A1 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2005-07-27 — — EP disclosed
WO-2004041817-A1 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2004-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics PNPO, PDXK, PLPBP MAPT 1995/4885KDM4E 2053/4885PKM 388/4885
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics PNPO, PLPBP, DPYD MAPT 2131/4885KDM4E 2813/4885PKM 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback